Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-t27h7 Total loading time: 0 Render date: 2025-02-23T13:14:41.191Z Has data issue: false hasContentIssue false

Pramipexole*

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Pramipexole ((S)-2-amino-4,5,6,7-tetrahydro-6(propylamino)benzothiazole dihydrochloride monohydrate) is a white to off-white powder, freely soluble in water. It is a dopamine agonist with a molecular weight of 302.3 and an empirical formula of C10H17N3S,2HCl,H2O.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 363 - 376
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Barone, P, Poewe, W, Albrecht, S, Debieuvre, C, Massey, D, Rascol, O, Tolosa, E, Weintraub, D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010: 9(6): 573–580.CrossRefGoogle Scholar
Rizos, A, Sauerbier, A, Falup-Pecurariu, C, Antonini, A, Martinez-Martin, P, Kessel, B, Henriksen, T, Silverdale, M, Durner, G, Chaudhuri, KR ; EUROPAR and the IPMDS Non-Motor PD Study Group. Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey. J Neural Transm (Vienna) 2020; 127(6): 875–879.CrossRefGoogle ScholarPubMed
Rota, S, Boura, I, Batzu, L, Titova, N, Jenner, P, Falup-Pecurariu, C, Chaudhuri, KR. ‘Dopamine agonist phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine. Expert Rev Neurother 2020; 20(9): 953–365.CrossRefGoogle ScholarPubMed
Silindir, M, Ozer, AY. The benefits of pramipexole selection in the treatment of Parkinson’s disease. Neurol Sci 2014; 35(10): 1505–1511.CrossRefGoogle Scholar
Wang, Y, Jiang, DQ, Lu, CS, Li, MX, Jiang, LL. Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: a systematic review and meta-analysis. Medicine (Baltimore) 2021; 100(44): e27511.CrossRefGoogle Scholar

References

Agüera-Ortiz, L, García-Ramos, R, Pérez, FJG, Lopez-Álvarez, J, Rodríguez, JMM, Rodríguez, FJA, Pueyo, JO, Valero, CP, Porta-Etessam, J. Focus on depression in Parkinson’s Disease: a Delphi consensus of experts in psychiatry, neurology, and geriatrics. Parkinson’s Dis 2021; 2021: 6621991.Google ScholarPubMed
AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 9 June 2022 via www.medicinescomplete.com.Google Scholar
Cardon-Dunbar, A, Robertson, T, Roberts, MS, Isbister, GK. Pramipexole overdose associated with visual hallucinations, agitation and myoclonus. J Med Toxicol 2017; 13(4): 343–346.CrossRefGoogle ScholarPubMed
Contin, M, Lopane, G, Mohamed, S, Callandra-Buonaura, G, Capellini, S, De Massis, P, Nassetti, S, Perrone, A, Riva, R, Sambati, L, Scaglione, C, Cortelli, P. Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson’s disease. Parkinsonism Relat Disord 2019; 61: 111–117.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 19 February 2023 via www.medicinescomplete.com.Google Scholar
Koschel, J, Chaudhuri, KR, Tönges, L, Thiel, M, Raeder, V, Jost, WH. Implications of dopaminergic medication withdrawal in Parkinson’s disease. J Neural Transm (Vienna) 2022; 129(9): 1169–1178.CrossRefGoogle ScholarPubMed
Latt, MD, Lewis, S, Zekry, O, Fung, VSC. Factors to consider in the selection of dopamine agonists for older persons with Parkinson’s disease. Drugs Aging 2019; 36(3): 189–202.CrossRefGoogle Scholar
Lazcano-Ocampo, C, Wan, YM, van Wamelen, DJ, Batzu, L, Boura, I, Titova, N, Leta, V, Qamar, M, Martinez-Martin, P, Chaudhuri, KR. Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice. Expert Rev Neurother 2020; 20(5): 477–495.CrossRefGoogle ScholarPubMed
Oguro, H, Kadota, K, Ishihara, M, Okada, K, Yamaguchi, S. Efficacy of pramipexole for treatment of apathy in Parkinson’s disease. Int J Clin Med 2014; 5: 885–889.CrossRefGoogle Scholar
Pramipexole. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 9 June 2022 via www.medicinescomplete.com.Google Scholar
Pramipexole. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 9 June 2022 via www.micromedexsolutions.com.Google Scholar
Seier, M, Hiller, A. Parkinson’s disease and pregnancy: an updated review. Parkinsonism Relat Disord 2017; 40: 11–17.CrossRefGoogle ScholarPubMed
Summary of product characteristics – Mirapexin 0.18 mg tablets. Boehringer Ingelheim Ltd. Electronic Medicines Compendium: MIRAPEXIN 0.18 mg tablets – summary of product characteristics (SmPC) – (emc). Accessed on 9 June 2022 via www.medicines.org.uk.Google Scholar
Wilson, SM, Wurst, MG, Whatley, MF, Daniels, RN. Classics in chemical neuroscience: pramipexole. ACS Chem Neurosci 2020; 11(17): 2506–2512.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Pramipexole*
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.039
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Pramipexole*
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.039
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Pramipexole*
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.039
Available formats
×